Listed

Opus Genetics, Inc.: Form 10-K for the period ended Dec 31, 2017

Filed with the SEC on Mar 9, 2018 and accepted by EDGAR at Mar 9, 2018, 16:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2017-01-01 to 2017-12-31$10.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-10-01 to 2017-12-31−$4.9mus-gaap:OperatingIncomeLoss
Operating income12 months2017-01-01 to 2017-12-31−$17.4mus-gaap:OperatingIncomeLoss
Net income3 months2017-10-01 to 2017-12-31−$3.6mus-gaap:NetIncomeLoss
Net income12 months2017-01-01 to 2017-12-31−$25.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-10-01 to 2017-12-31−$0.12us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2017-01-01 to 2017-12-31−$0.92us-gaap:EarningsPerShareBasicAndDiluted
Basic EPS3 months2017-10-01 to 2017-12-31−$0.12us-gaap:EarningsPerShareBasic
Cash and equivalentsAt period end2017-12-31$8.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-12-31$28.1mus-gaap:AssetsCurrent
Total assetsAt period end2017-12-31$28.3mus-gaap:Assets
Total liabilitiesAt period end2017-12-31$11.5mus-gaap:Liabilities
Shareholders' equityAt period end2017-12-31$16.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-18-012817. Last ingested by Listed: Nov 12, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.